U.S. markets close in 5 hours 49 minutes
  • S&P 500

    4,581.72
    +30.04 (+0.66%)
     
  • Dow 30

    35,671.10
    +180.41 (+0.51%)
     
  • Nasdaq

    15,359.72
    +123.89 (+0.81%)
     
  • Russell 2000

    2,282.85
    +30.36 (+1.35%)
     
  • Crude Oil

    82.50
    -0.16 (-0.19%)
     
  • Gold

    1,805.30
    +6.50 (+0.36%)
     
  • Silver

    24.25
    +0.06 (+0.26%)
     
  • EUR/USD

    1.1674
    +0.0068 (+0.58%)
     
  • 10-Yr Bond

    1.5610
    +0.0320 (+2.09%)
     
  • GBP/USD

    1.3790
    +0.0048 (+0.35%)
     
  • USD/JPY

    113.3730
    -0.4370 (-0.38%)
     
  • BTC-USD

    61,623.81
    +2,642.46 (+4.48%)
     
  • CMC Crypto 200

    1,483.50
    +64.12 (+4.52%)
     
  • FTSE 100

    7,235.09
    -18.18 (-0.25%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

Homology Medicines Regains Global Rights To Novartis Ophthalmology Program

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing technology platform for an ophthalmic target.

  • Novartis had concluded the collaboration and licensing agreement with Homology announced in 2017 to pursue other opportunities in their pipeline.

  • The company has generated in vivo data in two different eye targets.

  • "AAVHSC vectors can edit the back of the eye, and we plan to share additional data from the ophthalmology program at a scientific meeting in May," said Arthur Tzianabos, President and CEO of Homology Medicines.

  • Price Action: FIXX shares were trading 3.54% higher at $11.12, and NVS shares were up 0.8% at $86.61 in market trading hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.